Cell Line Information Sheet for LIM2405

Cell Line Designation: LIM2405
CellBank Catalogue No.: CBA-0165
Lot Number: 01651111S
Passage Number: 25
Total Cell Number: 4.0x 10⁶ cells
Expected Cell Viability: 94%

Brief Description: Adherent cell line derived from adenocarcinoma of the caecum of male patient.
Organism: Human (Homo Sapiens)
Tissue: Colon
Growth Properties: Adherent
Morphology: Epithelial

Growth Medium: RPMI1640 (with 2mM L-Glutamine + 25mM Hepes)+10%FCS, Insulin 0.6μg/ml, Hydrocortisone 1μg/ml, 1-Thioglycerol 10μM

Subcultivation Ratio: Split sub-confluent flasks (70-80% confluent) using 0.05%Trypsin/EDTA at 37°C for 5 minutes. The optimal split ratio is 1:4-1:6. Seeding density 1.6x10⁴ cells/cm².
Cells may take 2-3 days to seed after thawing or trypsinisation.
Establishing and Maintaining your Culture

Cells are maintained at 37°C and 5% CO₂. LIM2405 requires growth medium to be changed 3 times each week. Passage every 4-5 days. Refer to Technical & Customer Service Information pamphlet for further information.

Cryoprotectant Medium

10% DMSO + 90% FCS.

Biosafety Level

Cell line of human origin. Cellbank Australia recommends that cell lines be handled at category PC-2* containment level. *AS/NZS 2243.3:2010

Use Restrictions

These cells are distributed for research purposes only - refer to the Material Transfer Agreement (MTA).

Safety Precaution

Where cell lines are shipped as frozen ampoules there is a small risk that the ampoule may be pressurised, due to the expansion of trapped liquid nitrogen and could explode on warming. It is recommended that persons handling ampoules of frozen cells wear appropriate personal protective equipment including laboratory coat, insulated gloves and a full protective face shield.

Handling Procedure for Frozen Cells

Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability. Remove protective cryoflex layer around the ampoule prior to thawing. A precenrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.

Additional Information

Cells are adherent, spindly, grow as xenografts, heterozygous APC mutation (stop at aa 2198), B-Raf mutation (V600E), MSI, A33 negative.

Depositor

Professor Tony Burgess
Ludwig Institute for Cancer Research, Australia

Reference


Zhang H. et al. Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf
Int.J.Cancer 2009 July15; 125(2):297-307
While CellBank Australia uses reasonable efforts to include accurate and up-to-date information on this product sheet, CellBank Australia makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. CellBank Australia does not warrant that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, and use. CellBank Australia is not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to insure authenticity and reliability of strains on deposit, CellBank Australia is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the MTA for further details regarding the use of this product. The MTA is also available on our Web site at www.cellbankaustralia.com.